Cancer · 1982 · 42 citations · 7 references
MedicineOncologyPharmacologyChemotherapyGynecologic OncologyMedical OncologyChemotherapy Toxicity ManagementCombination ChemotherapyCytotoxic ChemotherapyEndometrial CancerGynecologic Cancer PharmacotherapyToxicity ManagementAnthracycline-based ChemotherapyDoxorubicin-based TherapyEndometrial Cancer Chemotherapy
In patients with advanced uterine corpus carcinoma treated with the combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA) or with this combination and 5-fluorouracil (MCAF), the overall response rate was 22%. There was no significant difference in response rates between the two regimens. There is some indication that survival was longer in ambulatory patients who were treated with MCA, but this combination produced more hematologic toxicity than MCAF. Patients unsuitable for treatment with doxorubicin received megestrol, 1-phenylalanine mustard, and 5-fluorouracil (MLF), which produced objective responses in 2 of 12 patients.
7
Carcinoma of the endometrium: Effect of stage and grade on survival
George D. Malkasian · Cancer · 1978 · 79 citations · Full text
Medicine, Gynecology, Oncology +13
Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer.
J.J. HORTON, Begg Cb, J Arseneault et al. · PubMed · 1978 · 64 citations
Medicine, Oncology, Pharmacology +11
Hydroxyprogesterone caproate therapy in advanced endometrial cancer
Edward C. Reifenstein · Cancer · 1971 · 58 citations · Full text
Medicine, Oncology, Pharmacology +16